Form 4 for KPTI Karyopharm Therapeutics Inc.
Accepted 2025-02-03 00:00:00 ET · period of report 2025-01-31 · accession 0000950170-25-012326 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-03 | 2025-01-31 | KPTI | Macomber Lori | EVP, CFO, Treas | A - Grant | $0.00 | +160.0K | 160.0K | New | $0 |
| D | 2025-02-03 | 2025-01-31 | KPTI | Macomber Lori | EVP, CFO, Treas | A - Grant | $0.00 | +650.0K | 650.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-31 | A | A | 160,000 | $0.00 | 160,000 | D | — | — | (F1) Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Inducement Stock Incentive Plan, as amended (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning January 31, 2026. |
| 2 | Derivative | Stock Option (right to buy) | 2025-01-31 | A | A | 650,000 | $0.00 | 650,000 | D | $0.62 · — to 2035-01-30 | 650,000 Common Stock | (F2) This option was granted on January 31, 2025 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on January 31, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter. |